Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-25T04:35:35.525Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmaceutical industry's perspective on health technology assessment

Published online by Cambridge University Press:  23 April 2004

Mickael Lothgren  and
Mark Ratcliffe
Mickael Lothgren
Affiliation:
European Health Economics (UK) Ltd.
Mark Ratcliffe
Affiliation:
European Health Economics (UK) Ltd.
Get access Rights & Permissions [Opens in a new window]

Abstract

This article presents the pharmaceutical industry's perspective on health technology assessment (HTA) with specific comments on the HTA systems in England and Wales, France, The Netherlands, and Sweden. The comments are focused on the following main themes: (i) The contributions of the HTA system to overall efficiency in the health-care system, (ii) HTA as a cost-driver for industry, patients, government, and society, and (iii) The various implementation barriers that currently exist for a successful implementation of HTA results.

Keywords

Health technology assessmentEfficiencyCostImplementation barriers
Type
Research Article
Information
International Journal of Technology Assessment in Health Care , Volume 20 , Issue 1 , January 2004 , pp. 97 - 101
Copyright
© 2004 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

ABPI. 2001 The costs of medicines—Good value for patients. ABPI Publication Brief. Ref: 528/01/6600X. Available at: www.abpi.org.uk. Accessed on February 17, 2003.
Berg M, van der Grinten T, Klazinga N. 2004 Technology assessments, priority setting, and appropriate care in Dutch health care. Int J Technol Assess Health Care. 20: 35– 43.Google Scholar
Carlsson P. 2004 Health technology assessment and priority setting for health policy in Sweden. Int J Technol Assess Health Care. 20: 44– 54.Google Scholar
Cookson R, McDaid D, Maynard A. 2001 Wrong SIGN, NICE mess: Is national guidance distorting allocation of resources. BMJ. 323: 743– 745.Google Scholar
Crump B, Drummond MF, Alexander S, Devaney C. 2000 Economic evaluation in the United Kingdom national health service. In: Graf von der Schulenburg J-M, ed. The influence of economic evaluation studies on health care decision-making: A European survey. Amsterdam: I.O.S. Press
Cutler DM, McCellan M. 2001 Is technological change in medicine worth it? Health Aff (Millwood). 20: 11– 29.Google Scholar
DiMasi JA, Caglarcan E, Wood-Armany M. 2001 Emerging role of pharmacoeconomics in the research and development decision-making process. Pharmacoeconomics. 19: 753– 766.Google Scholar
Drummond M, Cooke J, Walley T. 1997 Economic evaluation under managed care competition: Evidence from the UK. Soc Sci Med. 45: 583– 595. Google Scholar
Duthie T, Trueman P, Chancellor J, Diez L. 1999 Research into the use of health economics in decision making in the United Kingdom—Phase II. Is health economics for good or evil? Health Policy. 46: 143– 157. Google Scholar
Gafni A, Birch S. 2003 NICE methodological guidelines and decision making in the national health service in England and Wales. Pharmacoeconomics. 21: 149– 157. Google Scholar
Hoffmann C, Stoykova BA, Nixon J, et al. 2002 Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities. Value Health. 5: 71– 78. Google Scholar
Hutton J, Brown RE. 2002 Use of economic evaluation in decision-making: What needs to change? Value Health. 5: 65– 66. Google Scholar
Kleinke JD. 2001 The price of progress: Prescription drugs in the health care market. Health Aff (Millwood). 20: 43– 60. Google Scholar
NICE. Technical guidance for manufacturers and sponsors on making a submission to a technology appraisal. NICE March 2001.
Orvain J, Xerri B, Matillon Y. 2004 Overview of health technology assessment in France. Int J Technol Assess Health Care. 20: 25– 34. Google Scholar
Schubert F. 2002 Health technology assessment—The pharmaceutical Industry perspective. Int J Technol Assess Health Care. 18: 184– 191. Google Scholar
Sculpher M, Drummond M, O'Brien B. 2001 Effectiveness, efficiency, and NICE. A NICE start but evidence costs money. BMJ. 322: 943– 944. Google Scholar
Stevens A, Milne R. 2004 Health technology assessments in England and Wales. Int J Technol Assess Health Care. 20: 11– 24. Google Scholar
Towse A, Pritchard C. 2002 National institute for clinical excellence (NICE): Is economic appraisal working? Pharmacoeconomics. 20(Suppl 3): 95– 105.Google Scholar